Advances in DNA and mRNA-Based Strategies for Cancer Immunotherapy: Part A | Buch | 978-0-443-34495-4 | www.sack.de

Buch, Englisch, Format (B × H): 152 mm x 229 mm, Gewicht: 450 g

Advances in DNA and mRNA-Based Strategies for Cancer Immunotherapy: Part A


Erscheinungsjahr 2025
ISBN: 978-0-443-34495-4
Verlag: Elsevier Science & Technology

Buch, Englisch, Format (B × H): 152 mm x 229 mm, Gewicht: 450 g

ISBN: 978-0-443-34495-4
Verlag: Elsevier Science & Technology


Advances in DNA and mRNA-Based Strategies for Cancer Immunotherapy, Volume 165 in the Advances in Immunology series, presents current developments and comprehensive reviews in DNA and mRNA vaccines: Significant therapeutic approach against cancer management, Nanoparticles for mRNA-based cancer immunotherapy, Nucleic acid Delivery as a therapeutic approach in cancer immunotherapy, Plasmid DNA and mRNA: Delivery approaches and challenges, Viral & Non-viral Delivery of mRNA against Cancer Cell, Progress in Modifying and Delivering mRNA therapies for Cancer Immunotherapy, and more.

Other chapters cover mRNA-Based Cancer Vaccines: A Novel Approach to Melanoma Treatment, Therapeutic mRNAs for cancer immunotherapy: from structure to delivery, Harnessing the immune system: Insights into cancer vaccines, Lipid Nanoparticle-Mediated mRNA Delivery in Cancer Immunotherapy, Immunotherapy Perspectives in the Era of B-Cell Editing in Cancer Treatment, Personalized Precision: Revolutionizing Cancer Treatment with mRNA-Based Vaccines in Melanoma Therapy, Revolutionizing Cancer Treatment: Exploring Novel Immunotherapeutics, Checkpoints, bispecifics, and Vaccines in Development, and more.

Advances in DNA and mRNA-Based Strategies for Cancer Immunotherapy: Part A jetzt bestellen!

Weitere Infos & Material


1. DNA and mRNA vaccines: Significant therapeutic approach against cancer management.
2. Nanoparticles for mRNA-based cancer immunotherapy
3. Nucleic acid Delivery as a therapeutic approach in cancer immunotherapy
4. Plasmid DNA and mRNA: Delivery approaches and challenges
5. Viral & Non-viral Delivery of mRNA against Cancer Cell
6. Progress in Modifying and Delivering mRNA therapies for Cancer Immunotherapy
7. mRNA-Based Cancer Vaccines: A Novel Approach to Melanoma Treatment
8. Therapeutic mRNAs for cancer immunotherapy: from structure to delivery
9. Harnessing the immune system: Insights into cancer vaccines
10. Lipid Nanoparticle-Mediated mRNA Delivery in Cancer Immunotherapy
11. Immunotherapy Perspectives in the Era of B-Cell Editing in Cancer Treatment
12. Personalized Precision: Revolutionizing Cancer Treatment with mRNA-Based Vaccines in Melanoma Therapy
13. Revolutionizing Cancer Treatment: Exploring Novel Immunotherapeutics, Checkpoints, bispecifics, and Vaccines in Development
14. Recent progress, challenges (stability and in vivo distribution), and opportunities of DNA and mRNA Vaccine in cancer Immunotherapy


Prabhakar, Pranav Kumar
Dr. Pranav Kumar Prabhakar is currently working as a Professor in the Department of Biotechnology at Nagaland University, Kohima, Nagaland, India. He has been listed among the World's Top 2% Scientists (as published by Stanford University, USA, in 2021, 2022, 2023, and 2024). He earned his PhD in Biotechnology from IIT Madras. His primary research interests include elucidating molecular mechanisms and strategies for oral insulin delivery and mimicking signaling pathways in metabolic disorders (diabetes) using natural products. He is a member of the Royal Society of Chemistry and the Asia-Pacific Chemical, Biological & Environmental Engineering Society. He also serves as an editorial board member and reviewer for several reputed national and international journals. Dr. Pranav has received various honors, including a travel grant to attend ATTD 2009 in Greece, sponsored by the Indian Institute of Technology Madras and the Council for Scientific and Industrial Research (CSIR), and approved by the Department of Science and Technology (DST). He has published over 115 research articles in journals, authored or edited 17 books, contributed more than 40 book chapters, and delivered 9 oral and poster presentations at scientific meetings.

Ashique, Sumel
Sumel Ashique has been working as an assistant professor at Bengal College of Pharmaceutical Sciences & Research, Durgapur 713212, West Bengal, India, West Bengal, India. He has 3.5 years of teaching experience. He has achieved 70+ publications of International and national accredited reputed journals (Scopus, UGC). He has knowledge in drug delivery, nanotechnology and targeted treatment strategy. He has also 6 granted patents from IP and Australia & 20 book chapters have been submitted to well-known publishers like Springer, Elsevier, Bentham and Taylor & Francis. Currently he is editing 13 books under CRC Press, Taylor & Francis, Springer and Wiley.

Singh, Arun Kumar
Arun Kumar Singh completed his Master of Pharmacy (M. Pharm) in Pharmaceutics from Galgotias University, Greater Noida, India. He is currently an Assistant Professor in the Department of Pharmacy at Vivekanand Global University, where he is actively engaged in teaching and research.

His research interests encompass various emerging and interdisciplinary fields, including nano-formulation, blockchain technology, the Internet of Things (IoT), machine learning, cancer biology, artificial intelligence, big data analytics, and neuroscience. Demonstrating a strong commitment to academic excellence, Mr. Singh has made significant contributions to the scientific community.



Ihre Fragen, Wünsche oder Anmerkungen
Vorname*
Nachname*
Ihre E-Mail-Adresse*
Kundennr.
Ihre Nachricht*
Lediglich mit * gekennzeichnete Felder sind Pflichtfelder.
Wenn Sie die im Kontaktformular eingegebenen Daten durch Klick auf den nachfolgenden Button übersenden, erklären Sie sich damit einverstanden, dass wir Ihr Angaben für die Beantwortung Ihrer Anfrage verwenden. Selbstverständlich werden Ihre Daten vertraulich behandelt und nicht an Dritte weitergegeben. Sie können der Verwendung Ihrer Daten jederzeit widersprechen. Das Datenhandling bei Sack Fachmedien erklären wir Ihnen in unserer Datenschutzerklärung.